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OBJECTIVE: This study sought to determine the serum aminotransferase levels of patients with predialysis
chronic kidney disease and establish their relationships with serum creatinine levels and glomerular filtration
rate.
METHODS: Patients with chronic kidney disease were evaluated between September 2011 and May 2012.
Aminotransferase and creatinine serum levels were measured using an automated kinetic method, and
glomerular filtration rates were estimated using the Cockroft-Gault and Modification of Diet in Renal Disease
formulas to classify patients into chronic kidney disease stages.
RESULTS: Exactly 142 patients were evaluated (mean age: 64±16 years). The mean creatinine serum level and
glomerular filtration rate were 3.3±1.2 mg/dL and 29.1±13 mL/min/1.73 m2, respectively. Patients were
distributed according to their chronic kidney disease stages as follows: 3 (2.1%) patients were Stage 2; 54 (38%)
were Stage 3; 70 (49.3%) were Stage 4; and 15 (10.5%) were Stage 5. The mean aspartate aminotransferase and
alanine aminotransferase serum levels showed a reduction in proportion to the increase in creatinine levels
(p=0.001 and p=0.05, respectively) and the decrease in glomerular filtration rate (p=0.007 and p=0.028,
respectively). Alanine aminotransferase and aspartate aminotransferase serum levels tended to be higher
among patients classified as stage 2 or 3 compared with those classified as stage 4 or 5 (p=0.08 and p=0.06,
respectively).
CONCLUSIONS: The aspartate aminotransferase and alanine aminotransferase serum levels of patients with
predialysis chronic kidney disease decreased in proportion to the progression of the disease; they were
negatively correlated with creatinine levels and directly correlated with glomerular filtration rate.
KEYWORDS: Aspartate aminotransferase; Alanine aminotransferase; Creatinine; Chronic kidney disease;
Glomerular filtration rate.
Sette LH, Lopes EP. The reduction of serum aminotransferase levels is proportional to the decline of the glomerular filtration rate in patients
with chronic kidney disease. Clinics. 2015;70(5):346-349
Received for publication on February 4, 2015; First review completed on February 13, 2015; Accepted for publication on February 13, 2015
E-mail: setteluis@hotmail.com
*Corresponding author
’ INTRODUCTION
Aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) are markers of aggression to hepatocytes
and aid in the diagnosis, monitoring and treatment of liver
diseases because they reflect the inflammatory activity of the
liver (1–3). However, patients with chronic kidney disease
(CKD) on hemodialysis (HD) have lower aminotransferase
serum levels than those with preserved renal function, which
might adversely affect the assessment of liver injury among
these patients (4,5).
Some factors are implicated in the reduction of AST and
ALT serum levels among patients with CKD on HD such as
lower pyridoxine serum levels, higher homocysteine levels
and hemodilution due to fluid retention (6–8). In patients on
HD infected with the hepatitis B (HBV) or hepatitis C viruses
(HCV), other factors also contribute to the decrease in
aminotransferases, such as the lower viremia caused by the
dialysis procedure through the sequestration of the virus by
the dialyzer; the higher production of hepatocyte growth
factor (HGF), which is induced via dialysis and accelerates
liver regeneration; and the increased endogenous a-inter-
feron serum levels and lymphocyte activation that fight the
viral agent together (9–11).
However, most studies evaluating serum aminotransferase
levels have involved patients with CKD on HD, and only one
article has described a reduction in serum aminotransferaseDOI: 10.6061/clinics/2015(05)07
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levels among patients with predialysis CKD (12). In that
study, only the AST serum levels were correlated with the
creatinine concentration, whereas the relationship between
the aminotransferases and the glomerular filtration rate
(GFR) was not assessed; furthermore, this analysis was not
conducted according to CKD stage (12,13). In fact, the
behavior of AST and ALT serum levels during CKD
progression is still not fully known.
Therefore, this study aimed to determine the AST and ALT
serum levels of patients with predialysis CKD and correlate
them with their creatinine serum levels and GFRs.
’ PATIENTS AND METHODS
A cross-sectional study was conducted from September
2011 to May 2012 that included all of the patients older than
18 years who attended the CKD outpatient clinic of the
Nephrology Service, Hospital das Clínicas (UFPE) and who
were diagnosed with CKD at least 3 months previously.
The patients were consecutively selected using the follow-
ing criteria during their arrival at the clinic. Those with
positive serological markers for HBV, HCV, HIV or a chronic
liver disease were excluded, as were those who consumed
more than 210 g of alcohol/week, those with a manifest
infectious disease, and pregnant or postpartum women.
The patients who agreed to participate signed an informed
term of consent and completed a questionnaire regarding
their demographic, socioeconomic, anthropometric and
clinical data. Thereafter, approximately 5 mL of blood was
collected to perform biochemical testing using an automated
kinetic method (COBAS C501 ROCHE, Roche Diagnostics,
Indianapolis, Indiana, U.S.A.), which included evaluations of
their ALT, AST and creatinine levels.
When indicated, the test results were standardized for gender
by calculating the ratio of the value found by the method and
the upper limit of normal (ULN). Patients presenting ALT and
AST values greater than 5 times the ULN were excluded from
the analyses. Renal function was assessed using the creatinine
serum levels and by estimating the GFR with the Cockcroft-
Gault (CG) formula (13) corrected for body surface area (14) and
the abbreviated Modification of Diet in Renal Disease (MDRD)
equation (15).
The patients were classified into different CKD stages based
on the GFR (mL/min/1.73 m2) defined by the guidelines of the
Kidney Disease Outcomes Quality Initiative, such that GFR
490=Stage 1; between 60–89=Stage 2; between 30–59=Stage 3;
between 15–29=Stage 4; ando15 or under dialysis=Stage 5 (16).
The early CKD stages were defined as Stages 2 or 3, and the
advanced stages were categorized as Stages 4 and 5.
Initially, the population was described using a frequency dis-
tribution when the variable was categorical; means and standard
deviations were calculated when the variable was quantitative.
The Kolmogorov-Smirnov normality test was applied;
when the distribution was not normal, a logarithmic trans-
formation was applied to normalize the data. Student’s t test
(up to 2 levels) and ANOVA followed by a Bonferroni post
hoc test (42 levels) were applied to compare means.
Pearson’s chi-square test was applied to evaluate the
association between the CKD stages and the categorical
variables. A linear regression model was applied to analyze
the association with the GFR, and significant associations
were adjusted for BMI. All of the tests were conducted using
a significance threshold of 5% (po 0.05). STATAversion 12.0
was used for all data analyses.
The Research Ethics Committee of the Universidade Federal
de Pernambuco Health Sciences Center approved this study
under registration number 335/11, CAAE 0314.0.172.000-11.
This study follows the precepts set forth in Resolution No. 196/
96 of the (Brazilian) National Health Council.
’ RESULTS
During the study period, 191 patients were assessed, but
only 142 were included. The non-enrollment reasons for
these screened patients are shown in Figure 1.
The mean age of participants was 64±16 years, and 72
patients (51%) were male. The mean serum creatinine level
was 3.3±1.2 mg/dL, and the mean GFRs, as estimated using
the CG and MDRD equations, were 28.9±13 mL/min/1.73 m2
and 25.5±12.9 mL/min/1.73 m2, respectively. The major
drug groups that the patients used are listed in Table 1.
The patients were distributed across the CKD stages
according to the CG equation thusly: 3 (2.1%) patients were
classified as Stage 2; 54 (38%) were Stage 3; 70 (49.3%) were
Stage 4; and 15 (10.5%) were Stage 5. In addition, when the
Figure 1 - A flow chart of the patients who met the inclusion/
exclusion criteria for the study. ULN, AST and ALT.
Table 1 - The major medications used among the 142 patients
with predialysis CKD.
Major Medications in Use N %
ACE (angiotensin converting enzyme) inhibitors and ARBS
(angiotensin II receptor blockers)
77 54.2
Aspirin 61 43
Calcium channel blockers 63 44.3
B-Blockers 52 36.6
Diuretics 90 63.3
Erythropoietin-stimulation agents 13 9.1
Insulin 42 29.5
Alpha blockers 19 13.4
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MDRD equation was used, the following distribution was
noted: 3 (2.1%) patients were classified as Stage 2; 48 (33.8%)
were Stage 3; 73 (51.4%) were Stage 4; and 18 (12.6%) were
Stage 5. Because the number of Stage 2 patients was small
and their GFRs approximated those of the Stage 3 patients,
these patients were reclassified as Stage 3 for the purpose of
statistical analysis. The clinical and epidemiological char-
acteristic distributions are shown in Table 2.
The means of patients with regard to stage distribution as
evaluated using the CG and MDRD formulas were not
significantly different; therefore, we used the CG formula to
evaluate the variables.
The mean serum level divided by the AST or ALT ULNs
were 0.55 and 0.29, respectively. AST and ALT serum levels
above the ULN (41) were found in 6 (4.2%) and 2 (1.4%)
patients, respectively.
The AST and ALT serum level means reduced in
proportion to the increase in creatinine levels (p=0.001,
r= 0.27; and p=0.05, r= 0.17, respectively). In addition, the
mean ALT and AST serum levels were also reduced in
proportion to the descent in GFR (p=0.007 and p=0.028,
respectively; see Table 3).
Female patients had higher GFR levels, and significant
associations were observed with regard to the BMI and
aminotransferase measurements. The associations among
AST, ALT, and GFR remained significant after adjusting for
BMI (p=0.008 and p=0.039, respectively; see Table 3).
A significant difference was not detected when the
association of the AST and ALT serum levels were evaluated
for each CKD stage (p=0.16 and p=0.18, respectively). When
the earlier CKD stages (2 and 3) were combined and
compared with the more advanced stages (4 and 5),
significant trends in the ALT (p=0.08) and AST (p=0.06)
serum levels were observed, as described in Table 4.
Reductions of approximately 12% and 10% were observed
in the ALT and AST serum levels, respectively, when Stages 2
and 3 were compared with Stages 4 and 5.
’ DISCUSSION
Serum aminotransferase levels decrease in patients with
CKD who undergo HD (17); however, little is known with
regard to how the levels of these enzymes behave during the
earliest stages of CKD under predialysis treatment. This
study is the first to find a direct correlation between a
reduction in GFR and a decrease in aminotransferases.
In fact, we observed that AST and ALT serum levels
tended to be higher during the initial stages (2 and 3) of CKD
compared with the later stages (4 and 5). The possible
increases in the number of patients within each CKD stage
might reveal a more gradual and significant decrease in
serum aminotransferases levels; this finding is in line with
the reduction in the GFR. Importantly, the sample size must
be regarded as one of the limitations of this study.
Some hypotheses have been offered to explain the
reduction of serum aminotransferase levels among patients
with CKD on HD: a deficiency of pyridoxine, hemodilution
and hyperhomocysteinemia (6–8). In fact, Ono et al. reported
that patients with CKD on HD with pyridoxine deficiencies
have lower serum aminotransferase levels than those with-
out vitamin deficiencies (7). Lopes et al. observed
hemodilution and found that weight loss during HD was
associated with a rise in ALT serum levels (r=0.3, po0.001) (6).
Huang et al. evaluated the serum homocysteine levels of
145 patients undergoing HD and found that they were
negatively related to AST (r=0.4, po0.001). Thus, AST
serum levels might reflect the high metabolic activity of
homocysteine and influence its serum levels (8). Impor-
tantly, these hypotheses concern patients with CKD under
HD; however, they cannot be rejected with regard to
Table 2 - The distribution of clinical and epidemiological
characteristics according to the CKD stages of the 142 patients
with predialysis CKD.
Characteristic Stages of CKD p-value
Stages 2 & 3 Stage 4 Stage 5
N 57 70 15
Age* 65.3±12.9 63.2±17.4 60.2±22.1 0.506
BMI* 27.6±4.4 25.7±4.8 23.6±2.4 0.007a
Diabetic
Yes (%) 27 (47.3) 24 (34.2) 7 (46.7) 0.400
No (%) 30 (52.7) 46 (65.8) 8 (53.3)
Use of statin
Yes (%) 37 (64.9) 38 (54.2) 8 (53.3) 0.601
No (%) 20 (35.1) 32 (45.8) 7 (46.7)
No of medications 4.4±2.1 4.4±2.2 4.6±2.2 0.926
*ANOVA, post hoc Bonferroni test
**Pearson’s chi-squared test
aDifference between the patients with Stage 2 and 3 versus those with
Stage 4
Table 3 - A linear regression of the clinical and laboratory
characteristics according to the GFRs of the 142 patients with
predialysis CKD.
Characteristic GFR
Univariate analysis Adjusted by BMI
b coefficient p-value b coefficient p-value
Clinics
Age (years old) 0.03 0.625
Gender (F 4 M) 6.9 0.001 6.1 0.005
BMI* 24.1 0.000
Diabetes
(Yes 4 No)
1.4 0.546
Use of a statin
(Yes 4 No)
3.0 0.171 2.9 0.183
Number of
medication
0.43 0.408
Laboratory
AST/ULN* 8.87 0.007 8.40 0.008
ALT/ULN* 5.06 0.028 4.58 0.039
ULN: upper limit of normal
* Logarithmic transformation
Table 4 - The mean serum aminotransferase levels, divided by
the ULN for the early (2 and 3) and advanced (4 and 5) stages of
CKD among the 142 patients undergoing conservative
treatment.
Aminotransferase Stages of CKD p-value*
Early (2 & 3) Advanced (4 & 5)
N 57 85
AST/ULN 0.586±0.211 0.530±0.201 0.061
ALT/ULN 0.311±0.156 0.274±0.162 0.084
ULN: upper limit of normal
* Student’s t-test; measures with logarithmic transformation
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patients during predialysis. Therefore, another limitation
of this study is that it did not measure homocysteine or
pyridoxine.
Interestingly, this study found that almost all of the
patients had aminotransferase levels below the ULN, even
when they were using several potentially hepatotoxic drugs
(4 per patient on average) such as statins, which were used
by approximately 60% of the patients (18). Moreover, a
considerable number of patients had diabetes mellitus,
which might lead to liver inflammation (steatohepatitis)
and a consequent rise in liver enzymes (19).
Another interesting finding of this study concerns the
significant reduction in BMI based on CKD progression. This
behavior is explained not only by the fact that patient weight is
included in the calculation of the GFR but also given the
malnutrition associated with CKD (13,20,21). In fact, the
progressive decrease of BMI might reduce dyslipidemia or
glucose levels, thereby promoting a regression of underlying
fatty liver disease that contributes to decreased aminotransfer-
ase levels (22). To reduce this possible confound, the association
between GFR and aminotransferases was adjusted for BMI;
however, it remained significant. Moreover, malnutrition might
reduce the stocks of B-complex vitamins, especially pyridoxine,
which act as a co-factor in the synthesis of aminotransferases by
reducing their production (23).
Male patients presented lower GFRs than their female
counterparts. This finding might be related to the CKD
progression rate, which occurs more rapidly in males,
thereby increasing the chances that these patients are at
more advanced stages of the disease (24).
This preliminary study revealed that the decrease in AST
and ALT serum levels among patients with CKD occurs
before the start of dialysis, and these enzymes are indepen-
dently decreasing factors associated with HD. Future studies,
should collect larger samples of patients with CKD to
evaluate the evidence of aminotransferase reduction in these
patients, such as pyridoxine and homocysteine serum levels.
In conclusion, the AST and ALT serum levels of patients
with pre-dialysis CKD tended to decrease in proportion to
their CKD progression, and these levels were negatively
correlated with their creatinine serum levels and directly
correlated with the GFR.
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